TVTX vs. TRDA, TBPH, STTK, CDMO, SLRN, LXRX, IGMS, ANL, FULC, and LRMR
Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Entrada Therapeutics (TRDA), Theravance Biopharma (TBPH), Shattuck Labs (STTK), Avid Bioservices (CDMO), Acelyrin (SLRN), Lexicon Pharmaceuticals (LXRX), IGM Biosciences (IGMS), Adlai Nortye (ANL), Fulcrum Therapeutics (FULC), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical preparations" industry.
Entrada Therapeutics (NASDAQ:TRDA) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.
Entrada Therapeutics presently has a consensus price target of $21.00, indicating a potential upside of 68.67%. Travere Therapeutics has a consensus price target of $18.00, indicating a potential upside of 242.21%. Given Entrada Therapeutics' higher possible upside, analysts clearly believe Travere Therapeutics is more favorable than Entrada Therapeutics.
86.4% of Entrada Therapeutics shares are owned by institutional investors. 7.6% of Entrada Therapeutics shares are owned by insiders. Comparatively, 3.8% of Travere Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Travere Therapeutics had 18 more articles in the media than Entrada Therapeutics. MarketBeat recorded 18 mentions for Travere Therapeutics and 0 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.45 beat Travere Therapeutics' score of 0.00 indicating that Travere Therapeutics is being referred to more favorably in the news media.
Entrada Therapeutics has a beta of -0.5, indicating that its stock price is 150% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.
Entrada Therapeutics has higher earnings, but lower revenue than Travere Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.
Travere Therapeutics received 40 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Entrada Therapeutics an outperform vote while only 47.66% of users gave Travere Therapeutics an outperform vote.
Entrada Therapeutics has a net margin of -5.18% compared to Entrada Therapeutics' net margin of -56.02%. Travere Therapeutics' return on equity of -2.89% beat Entrada Therapeutics' return on equity.
Summary
Entrada Therapeutics beats Travere Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Travere Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Travere Therapeutics Competitors List
Related Companies and Tools
